Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 70

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 70
---
 up to 105,843 Common Shares issued to such holders
(the “Existing Warrants”). The October Warrant Amendment makes certain adjustment to the definition of a “Fundamental
Transaction” in Section 3(e) of the Existing Warrants. In exchange for the October Warrant Amendment, we agreed to adjust the
exercise price in the Common Warrants to CHF 0.80 and issued to the holders pre-funded warrants to purchase up to 136,648 Common Shares
(the “October Pre-Funded Warrants”). Each October Pre-Funded Warrant is exercisable for one Common Share at an exercise price
of CHF 0.80 per share. The October Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the October
Pre-Funded Warrants are exercised in full.

On October 10, 2024,
we successfully implemented a restructuring measure by converting the claims of related party debt holders in the amount of $2,788,650
into 493,986 Common Shares. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the
debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations.

On December 4, 2024,
we entered into a securities purchase agreement with an accredited investor, providing for the issuance in a private placement offering
of 322,580 registered Common Shares, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1 million.
The offering was structured in two tranches, with the first tranche of $500,000 closing in January 2025 following shareholder approval.
The proceeds from the offering were intended to support our general corporate purposes and our proposed Merger with Kadimastem. The second
tranche of $500,000 may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including
the receipt of shareholder approval and the Common Shares trading for at least ten consecutive trading days above the purchase price of
$3.10, which corresponds to an approximate 15% premium. The Company uses and intends to further use the net proceeds from the offering
for working capital and general corporate purposes.

On March 27, 2025, we
entered into a securities purchase agreement with three accredited investors (the “March 2025 SPA”). Pursuant to the terms
of the March 2025 SPA, the Company agreed to